Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 07, 2023 at 07:02 am EDT
Share
Protalix BioTherapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 35.08 million compared to USD 8.75 million a year ago. Net income was USD 19.34 million compared to net loss of USD 5.33 million a year ago. Basic earnings per share from continuing operations was USD 0.29 compared to basic loss per share from continuing operations of USD 0.11 a year ago. Diluted earnings per share from continuing operations was USD 0.21 compared to diluted loss per share from continuing operations of USD 0.11 a year ago.
For the six months, revenue was USD 44.66 million compared to USD 24.84 million a year ago. Net income was USD 16.21 million compared to net loss of USD 7.62 million a year ago. Basic earnings per share from continuing operations was USD 0.26 compared to basic loss per share from continuing operations of USD 0.16 a year ago. Diluted earnings per share from continuing operations was USD 0.18 compared to diluted loss per share from continuing operations of USD 0.16 a year ago.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
PROTALIX BIOTHERAPEUTICS, INC. 
